Last mentioned: Mar 10, 2026
Document Request
Expected date for formal requests for internal FDA communications regarding DMD drug applications.
Initial Inquiry
The Senator's office begins requesting data on DMD drug approval timelines and internal CBER deliberations.
Investigation Announced
Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.
Commissioner Consultation
Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.
Investigation Announced
Sen. Ron Johnson announces a formal probe into the FDA's handling of rare disease drug applications.
Commissioner Meeting
Johnson meets with FDA Commissioner Marty Makary to discuss specific biologic therapy rejections.
Senator Ron Johnson (R-Wisc.) has launched an investigation into the FDA's regulatory hurdles for rare disease treatments, specifically targeting biologics for Duchenne muscular dystrophy. The probe follows a direct meeting with FDA Commissioner Marty Makary and signals a significant escalation in political pressure on the agency's approval standards.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA's handling of biologic therapy applications for rare diseases, specifically targeting Duchenne muscular dystrophy. The probe follows a direct consultation with FDA Commissioner Marty Makary regarding perceived regulatory barriers for life-saving treatments.
Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.
FDA Commissioner Marty Makary is reportedly attempting to hire Dr. Tracy Beth Hoeg to lead a new initiative focused on antidepressant safety. The move is tied to a proposed 'bold new warning' for SSRIs and SNRIs, potentially addressing persistent side effects that have long been a point of contention between regulators and the pharmaceutical industry.